Since 2014, Magnosco has stood for technological innovation in skin cancer diagnostics. As a MedTech startup based in Berlin-Adlershof, we combine user-centered product development, , AI-supported analysis, and scientific research to create smart solutions for dermatology.

About us
Shaping the future of dermatoscopic diagnostics
Our history
The foundation for Magnosco was laid around the year 2000: Dr. Matthias Scholz (LTB Lasertechnik Berlin) and Dr. Dieter Leupold developed dermatofluoroscopy – a new method for skin cancer diagnostics – as part of intensive research work. The idea of founding a company from this followed in 2010. Magnosco was officially launched in 2014 with the aim of bringing this pioneering technology to series production.
Today, Magnosco is managed by Thomas Diepold and Dr. Sebastian Ahlberg. The team consists of 20 to 25 experts from the fields of medicine, technology, product development and AI.
Our history
Our vision
We shape the future of dermatoscopic diagnostics.
We want to revolutionise skin cancer detection. Our drive is to improve the patient experience across the entire diagnostic journey – faster, more comprehensible and more effective. With the help of AI, smart tools and intuitive design, we shape the dermatology diagnostics of the future.
Creative ideas and curiosity are welcome
A diverse, inclusive, bonded team no matter culture, color, gender, etc. is our energy
Honesty, trust and transparency are the key to success and feedback is highly appreciated
Agility and a pro-active mindset drive our work
User-centric development is our mantra
Everyone always gives their best to achieve the highest quality
We are a diverse, international team with great vision, high ownership and strive for real change.
What sets us apart:
Reliable technologies: Our medical products sustainably improve skin cancer diagnostics.
Simplicity & ergonomics: Our products fit into existing workflows and set new standards in design.
Scientific validation: Clinical studies, medical principles and close collaboration between development and research.
Certified quality: EN ISO 13485, CE according to MDR, tested IT security according to DIN EN IEC 81001-5-1.
Awards: Red Dot Award 2024, German Medical Award 2023, Focus Design Award 2024, iF Design Award 2025.

Our
core competencies

Why “Magnosco”?
The name “Magnosco” is derived from the Latin word agnoscere – to recognize.
“Magnosco” means: I recognize the melanoma. That is our goal.
Our history and research have paved the way to make dermatological diagnostics simpler, more objective, and more efficient.
The challenge that drives us
The objective assessment of skin changes is one of the greatest challenges in dermatology. A lack of specialist availability, overdiagnosis, long waiting times, and uncertainty lead to frustration. We develop solutions that digitally enhance and refine dermatological expertise – making it more precise and accessible for all.
The challenge that drives us
Our partners
We have numerous partnerships,
that drive us forward.
Here is a selection.
Our partners
We have numerous partnerships,
that drive us forward.
Here is a selection.